Pluristem's South Korean Partner Files IND with Korean FDA for PLX Cells
On the heels of announcing its strategic partnership agreement with Cha Bio&Diostech on June 26th, Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapies, announced today that Cha Bio&Diostch “Cha” has filed its first investigational new drug (IND) application for Pluristem’s PLacental eXpanded (PLX) cells with the Korea Food and Drug Administration (FDA). This IND is for the use of PLX-PAD in the treatment of intermittent claudication (IC) and mirrors the clinical protocols implemented by Pluristem in its U.S....
View full press release